research use only

LNP023 (Iptacopan) Hydrochloride Factor B inhibitor

Name: LNP023 (Iptacopan) Hydrochloride
Brand: Selleck Chemicals
SKU: E0119
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E0119

Iptacopan (LNP023) Hydrochloride is a first-in-class, orally administered, potent and highly selective factor B inhibitor with an IC50 of 12 nM and a Kd value of 7.9 nM. Iptacopan exhibits excellent selectivity over other proteases affording IC50s of >30 μM across a panel of 41 human proteases.

Chemical Structure

Molecular Weight: 458.98

Jump to

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor
Other Immunology & Inflammation related Inhibitors	Cl-amidine Bestatin (Ubenimex) Bindarit (AF 2838) Tempol Tranilast GI254023X (GI4023) Sinomenine Geniposidic acid CORM-3 Germacrone

Solubility

In vitro
Batch:

DMSO : 85 mg/mL (185.19 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 85 mg/mL

Water : 5 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	458.98	Formula	C₂₅H₃₁ClN₂O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1646321-63-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	factor B 12 nM
References	[1] https://pubmed.ncbi.nlm.nih.gov/32073845/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-07)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03955445	RECRUITING	C3 Glomerulopathy; Immune-complex-membranoproliferative Glomerulonephritis	Novartis Pharmaceuticals	2019-10-03	PHASE3
NCT05795140	RECRUITING	Atypical Hemolytic Uremic Syndrome	Novartis Pharmaceuticals	2024-05-08	PHASE3
NCT06934967	RECRUITING	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Novartis Pharmaceuticals	2025-10-28	PHASE3
NCT04557462	ACTIVE_NOT_RECRUITING	Primary IgA Nephropathy	Novartis Pharmaceuticals	2021-09-20	PHASE3
NCT06994845	RECRUITING	Primary Immunoglobulin A Nephropathy (IgAN)	Novartis Pharmaceuticals	2025-11-27	PHASE3
NCT05755386	RECRUITING	IC-MPGN	Novartis Pharmaceuticals	2023-10-02	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):